Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate... As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.
- Mechanism
- Curator reviewed
Anecortave acetate functions as an antiangiogenic agent, inhibiting blood vessel growth by decreasing extracellular protease expression and inhibiting endothelial cell migration. Its angiostatic activity does not seem to be mediated through any of the commonly known pharmacological receptors. (Ophthalmology 2004;111:2316-7) RETAANE blocks signals from multiple growth factors because it acts downstream and independent of the initiating angiogenic stimuli and inhibits angiogenesis subsequent to the angiogenic stimulation.
- Primary indication
- Investigated for use/treatment in glaucoma and macular degeneration.Curator reviewed
- Formula / weight
- C23H30O5 · 386.4813 g/mol (avg)
- Code names
- AL-3789
Resolves to
YUWPMEXLKGOSBF-GACAOOTBSA-NSMILES[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12CWhat you can answer from here — as of February 21, 2021
Which companies are running trials of Anecortave acetate, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account